about
Cleavage of cystatin C is not associated with multiple sclerosisCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeRelation between pro-inflammatory cytokines and acetylcholine levels in relapsing-remitting multiple sclerosis patientsPaternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.Independent component analysis for the extraction of reliable protein signal profiles from MALDI-TOF mass spectra.Pre-analytical factors in clinical proteomics investigations: impact of ex vivo protein modifications for multiple sclerosis biomarker discovery.Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study.Protein profiling of Guillain-Barrè syndrome cerebrospinal fluid by two-dimensional electrophoresis and mass spectrometry.Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyThe Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): normative values with gender, age and education corrections in the Italian population.Unmet needs of people with severe multiple sclerosis and their carers: qualitative findings for a home-based intervention.Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study.Oxidative modifications of cerebral transthyretin are associated with multiple sclerosis.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisNeopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patientsSafety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Predictors of disability worsening in clinically isolated syndrome.Patient expression of emotions and neurologist responses in first multiple sclerosis consultationsMale Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSImproving patient-physician dialog: commentary on the results of the MS Choices survey.A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patientsNatalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.Development of a Short Version of MSQOL-54 Using Factor Analysis and Item Response Theory.The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study.Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure.Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group.Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.Increasing age at disability milestones among MS patients in the MSBase Registry.Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice.Prognostic indicators in pediatric clinically isolated syndrome.Defining secondary progressive multiple sclerosis.Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study.Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
P50
Q28265824-F20B0D2D-78D9-4418-9F20-4F80D98A881CQ28480907-C8AE104D-E961-4980-AD48-556CC670A31CQ30460434-511519EC-4FBB-4968-AD49-D46CBCA4F94EQ31162052-54592240-B2C2-4671-8232-C193ED890156Q33305606-5A70C3CD-57AD-45C0-BBF6-DE911F08FEE9Q33492026-8E23BEF5-F879-45C6-BF77-768C5518A418Q33569305-689CC3EB-D69C-4A8B-AD2B-DF7C2BB06371Q33676621-CFB9B448-08FE-4B0B-A1D4-D1D9670181AAQ34184837-F4BDFDEA-7D71-4C9B-8845-02EAE729F365Q34234374-8C268F7A-B927-4620-9641-91DF8D311533Q34294345-013378A0-580C-4459-8C8D-778C8B3AB038Q34527935-04D0D5D1-DF12-4B34-ACED-0E00EA22E782Q34547996-62554839-1F68-42E3-856D-2E77A7F8AE9AQ34737478-23189F3E-413F-4DD2-965C-7ED278326BB2Q35009131-D7FB83FA-05CD-4E2A-8F14-715BE7E6411FQ35136988-DCC9A13B-FF7A-4470-987A-AB6F49802BDAQ35469575-9F6BB4B4-1913-487E-8F43-38F666199912Q35619185-5BA8E0F0-7DDA-453B-886B-9B2EBA10903DQ35648386-015F9C7F-E2A4-4174-9370-45DDD837B0A3Q35653675-4E920E19-56BD-46A4-AD2F-2517C5F46E64Q35780959-ED132749-4924-4071-B2AE-34FAA332D213Q35809567-7DBB1545-A45D-48C8-8A04-65EB201454ACQ35939675-ADAEDCE3-FDA2-4C6D-9ADA-D126F8955B7DQ35989801-E54D97A7-22BA-4406-8FE6-C7206973B78CQ36062456-4FE74A04-8D46-482B-BC83-506ED04F22EDQ36367612-C8ADC68A-53B7-4068-A5B4-0BEAECE67B3FQ36789883-FCE0796E-B778-4527-92AE-8D4C029483E2Q37321449-5D8BBF9A-3BC0-487A-99BF-4E93DD8E729BQ38174450-B963BBAB-FFA2-4497-AB33-386980D434C7Q38238548-E89CB165-9A43-4E7C-B6DF-388313DFB546Q38289267-BC5B6679-2063-4D39-BA6B-FD7757ACD36FQ38433183-6C1EE8DC-4ECC-4DFC-8102-33FD95A9017AQ38752797-0EEEB705-045E-439F-A953-D6B18B4F8CF6Q38791015-CE809D67-FBF6-4676-9194-BCF22B9D20DAQ38821503-1B0229C3-1AD1-49F6-8F17-635A8D5BFC1BQ38843046-B8A7F3BE-B9B2-4B69-8B46-5A196B056279Q38850911-BA4BFF85-5560-4BD2-A945-1B754B67C433Q38956663-4760142A-F972-4D73-A6DA-901F04320ACAQ39139645-97FBF4F8-EF34-4A25-9CD1-CE2132A390BEQ39685700-2E0A0ECA-9FBE-4A34-881C-9EC1768A72C2
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Alessandra Lugaresi
@ast
Alessandra Lugaresi
@en
Alessandra Lugaresi
@es
type
label
Alessandra Lugaresi
@ast
Alessandra Lugaresi
@en
Alessandra Lugaresi
@es
prefLabel
Alessandra Lugaresi
@ast
Alessandra Lugaresi
@en
Alessandra Lugaresi
@es
P214
P244
P1053
C-7743-2012
P106
P1153
7004836896
P21
P213
0000 0000 3887 6412
P214
P244
no00074564
P31
P3829
P496
0000-0003-2902-5589
P735
P7859
lccn-no00074564